Marksans Pharma gains on UK health regulator nod to market new oral solution

Over the past year, the stock has rewarded shareholders with 120 percent returns.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Marksans Pharma shares gained over two percent in trade on May 28 after the pharma player received the UK health regulator's nod to market its new oral solution.

The firm's wholly owned subsidiary Relonchem has received the marketing authorization for Levetiracetam Relonchem 100 mg/mL Oral Solution from UK MHRA. The product will be manufactured at the Group’s UK manufacturing facility.

Levetiracetam is a medication that is used to treat epilepsy, and helps control certain types of seizures.

At 11.45 am, Marksans Pharma shares were quoting Rs 167.8 on the BSE, higher by 1.94 percent as against the previous session's close.

Follow our market blog to catch all the live updates

On April 15, Massachusetts Institute of Technology (MIT) bought a 1.45 percent stake or 66 lakh shares in Markans Pharma. Despite minimal information or market buzz about the stock, it has quietly become a multibagger. Over the past year, the stock has rewarded shareholders with 120 percent returns.

Apart from MIT's stake, nine other fund houses have a cumulative 4.23 percent ownership in the drug maker. Aside from that, Quant Smallcap Fund holds a 2.79 percent stake and OrbiMed Asia IV Mauritius FVCI has a 10.88 percent ownership of the company.

The company's product portfolio is skewed towards over-the-counter segments and soft gel products mainly in the US and UK markets. The thing about OTC drugs is that the segment is much more stable as compared to traditional generics that often face concerns of price erosion.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.